Name (Synonyms) | Correlation | |
---|---|---|
drug331 | BBV152B Wiki | 1.00 |
drug3207 | blood sample for seroepidemiological investigation Wiki | 1.00 |
drug332 | BBV152C Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study is designed to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of BBV152 vaccine formulations. A total sample size of 1125 healthy volunteers, with 375 and 750 volunteers in phase 1 and 2 studies, respectively.
Description: Safety
Measure: Phase 1: Occurrence of adverse events and Serious Adverse events Time: Through study completion, an average of 6 monthsDescription: Pre- and Post-vaccination immune response
Measure: Phase 2: Evaluation of Neutralizing Antibody Titers Time: Through study completion, an average of 6 monthsDescription: Pre- and Post-vaccination immune response
Measure: Phase 1: Evaluation of Neutralizing Antibody Titers Time: Through study completion, an average of 6 monthsDescription: Safety
Measure: Phase 2: Occurrence of adverse events and Serious Adverse events Time: Through study completion, an average of 6 months